Начало・Списък с акции・PTC Therapeutics Inc

PTC Therapeutics Inc

Затворен

СекторЗдравеопазване

69.05 1.69

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

69.73

Ключови измерители
By Trading Economics
Приходи	132M -2.8M
Продажби	108M 273M
P/E Средно за сектора	7.597 64.641
EPS	-0.03
Марж на печалбата	-1.031
Служители	991
EBITDA	35M -36M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+44.35% upside

Дивиденти
By Acuity
Следващи печалби	3.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	858M 6.3B
Предишно отваряне	67.36
Предишно затваряне	69.05

Настроения в новините

By Acuity

24%

76%

67 / 340 Класиране в Healthcare

PTC Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:46 ч. UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31.07.2026 г., 21:01 ч. UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30.07.2026 г., 22:31 ч. UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29.07.2026 г., 18:26 ч. UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28.07.2026 г., 18:31 ч. UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27.07.2026 г., 20:06 ч. UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22.07.2026 г., 17:16 ч. UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21.07.2026 г., 18:01 ч. UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20.07.2026 г., 19:56 ч. UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Сравнение с други в отрасъла

Ценова промяна

PTC Therapeutics Inc Прогноза

Ценова цел

By TipRanks

44.35% нагоре

12-месечна прогноза

Среден 98.33 USD 44.35%

Висок 130 USD

Нисък 70 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за PTC Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на PTC Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

67 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.